Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases Academic Article uri icon

Overview

MeSH Major

  • Autoantibodies
  • Carcinoma, Small Cell
  • Lung Neoplasms
  • Neurons
  • Paraneoplastic Syndromes

abstract

  • Pulse/continuous-dose erlotinib produced a 74% overall response rate and a 75% response rate in brain metastases in patients with EGFR-mutant lung cancers and untreated brain metastases. CNS control persisted even after progression elsewhere. Although this regimen did not improve progression-free survival or delay the emergence of EGFR T790M, it prevented progression in the brain and could be useful in situations in which CNS control is critical. Cancer 2018;124:105-9. © 2017 American Cancer Society.

publication date

  • January 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5735028

Digital Object Identifier (DOI)

  • 10.1002/cncr.30990

PubMed ID

  • 28940498

Additional Document Info

start page

  • 105

end page

  • 109

volume

  • 124

number

  • 1